Publications by authors named "Shira Ashkenazi"
Immunotherapy has revolutionized cancer treatment, yet most patients do not respond. Here, we investigated mechanisms of response by profiling the proteome of clinical samples from advanced stage melanoma patients undergoing either tumor infiltrating lymphocyte (TIL)-based or anti- programmed death 1 (PD1) immunotherapy. Using high-resolution mass spectrometry, we quantified over 10,300 proteins in total and ∼4,500 proteins across most samples in each dataset.
View Article and Find Full Text PDFNecrotizing pneumonia is a severe form of pneumonia that is mainly treated with conservative treatment, including antibiotics. We report a unique case of necrotizing pneumonia due to group A streptococcus infection in an 18-month-old boy who required extracorporeal membrane oxygenation (ECMO) support. Following surgical lobectomy, the child was weaned off ECMO and recovered uneventfully.
View Article and Find Full Text PDFAs melanoma cells are immunogenic, they instigate an adaptive immune response and production of anti-tumor T-cells. A central factor in this interaction is CEACAM1 (carcinoembryonic antigen cell adhesion molecule 1), a transmembrane glycoprotein previously shown in our lab to protect melanoma cells from T cell-mediated killing. In this study, we examine the role of transcription factor SOX9 in the regulation of CEACAM1 expression and immune resistance in melanoma cells.
View Article and Find Full Text PDFArticle Synopsis
- - The study reveals that the RNA editing protein ADAR1 is down-regulated during the metastatic transition of melanoma, which increases melanoma cell growth and tumor characteristics.
- - Knockdown of ADAR1 in melanoma cells leads to resistance against tumor infiltrating lymphocytes, indicating a significant role for ADAR1 in melanoma immune resistance through its effect on miR-222 and ICAM1 expression.
- - Higher levels of miR-222 in melanoma tissues correlate with poor clinical response to the drug ipilimumab, suggesting miR-222 could serve as a biomarker to predict treatment outcomes and inform personalized therapy.